International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges -
3 hours ago
- #Immune Reconstitution Therapy
- #Multiple Sclerosis
- #Disease-Modifying Therapy
- Cladribine tablets (CladT) are recommended as a rational option for patients with relapsing-remitting multiple sclerosis (RMS) who experience intractable safety/tolerability issues on high-efficacy disease-modifying therapies (DMTs).
- CladT is also suggested for older patients with stable RMS who have been on long-term DMT, and for those with breakthrough disease activity despite treatment with S1P modulators.
- The interval between stopping an anti-trafficking DMT (especially S1P modulators) and starting CladT should be minimized to prevent rebound RMS disease activity.
- CladT may be considered for patients with breakthrough RMS disease activity on anti-CD20 treatment in selected cases.
- Immune reconstitution therapy with CladT offers an opportunity for family planning by allowing treatment without continuous DMT.